This was not entirely unexpected as there is considerable heterogeneity in susceptibility of MM cell lines to LCL161 (23), which may be in part be due to deletions of cIAP1/2 or other NF-κB-associated factors that occur in some multiple myelomas (24, 25). This evidence concerns the gene BIRC2 and plasma cell myeloma.